{
    "clinical_study": {
        "@rank": "102567", 
        "acronym": "LID", 
        "arm_group": [
            {
                "arm_group_label": "Standard Care", 
                "arm_group_type": "Other", 
                "description": "This arm will receive standard care for Type 2 diabetes: exercise and diet counseling according to the American Diabetes Association recommendations."
            }, 
            {
                "arm_group_label": "Optimum Lifestyle intervention", 
                "arm_group_type": "Experimental", 
                "description": "This arm will be participate in weekly visits with a dietitian and 4 weekly supervised exercise sessions. They will be advised to follow a high-protein, low-carbohydrate diet."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of lifestyle intervention on metabolism\n      and blood sugar control in Type 2 Diabetics."
        }, 
        "brief_title": "Diet and Exercise Intervention in Type 2 Diabetes", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 30-64 yrs old\n\n          2. BMI 28.0-42.0 kg/m2\n\n          3. Diagnosis of type 2 diabetes based on HbA1C>6.5% or results of an oral glucose\n             tolerance test or current use of anti-diabetic medications\n\n          4. Reported duration of type 2 diabetes <8years\n\n          5. HbA1C \u22648.5 %.\n\n          6. Work at Washington University in St. Louis, Barnes Jewish Hospital or St. Louis\n             Childrens Hospital.\n\n        Exclusion Criteria:\n\n          1. Diabetes therapy with long-acting Glucagon-like peptide-1 agonist (i.e. Bydureon),\n             thiazolidinedione, or insulin\n\n          2. Any change in diabetes medication in previous 3 months\n\n          3. Unstable weight (>2% change during the last 2 months before entering the study)\n\n          4. History or evidence of serious pulmonary or cardiovascular disease, including acute\n             coronary syndrome, heart failure requiring medications, or New York Heart Association\n             class III heart failure (patients with marked limitation of activity and who are\n             comfortable only at rest) or IV heart failure (patients who should be at complete\n             rest, confined to bed or chair and who have discomfort with any physical activity).\n\n          5. Evidence of serious cardiac abnormalities during exercise stress testing that\n             increase cardiac risk of initiating an exercise program.\n\n          6. Creatinine >1.5 mg/dL\n\n          7. Microalbuminuria; spot urine albumin:creatinine ratio >30 (30 \u03bcg albumin/mg\n             creatinine)\n\n          8. Coagulation disorders\n\n          9. Anemia (Hemoglobin <10.0 g/dL)\n\n         10. Liver enzymes (ALT and AST) \u22653 times the upper limit of normal\n\n         11. Uncontrolled proliferative diabetic retinopathy\n\n         12. Severe peripheral neuropathy diagnosed by monofilament testing\n\n         13. Severe organ dysfunction\n\n         14. Pregnant or breastfeeding\n\n         15. Participating in regular exercise (>1 h of structured exercise/week)\n\n         16. Joint replacement within the last year\n\n         17. Smokes tobacco\n\n         18. Severe lactose intolerance\n\n         19. Take any medication that might interfere with interpretation of the metabolic studies\n\n         20. Unable or unwilling to follow the study protocol or for any reason the research team\n             believes the volunteer is not an appropriate candidate for this study, including\n             non-compliance with screening appointments or previous medical visits."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977560", 
            "org_study_id": "201302095"
        }, 
        "intervention": [
            {
                "arm_group_label": "Optimum Lifestyle intervention", 
                "description": "Participants will follow a high-protein, low-carbohydrate diet and participate in supervised exercise,", 
                "intervention_name": "Optimum Lifestyle Intervention", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Standard Care", 
                "description": "Participants will be given advice on exercise and the American Diabetes Association diet, as if they went to a Diabetes clinic.", 
                "intervention_name": "Standard Care", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "exercise", 
            "high protein"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Diet and Exercise Intervention in Type 2 Diabetes", 
        "other_outcome": {
            "description": "Plasma lipid profile; markers of inflammation, body fat distribution (visceral adipose tissue (VAT) intrahepatic triglyceride (IHTG) content and intramyocardial TG content), and cardiovascular structure and function", 
            "measure": "Cardiovascular risk factors", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "overall_contact": {
            "email": "hparker@dom.wustl.edu", 
            "last_name": "Helene M Parker, BA", 
            "phone": "314-747-2627"
        }, 
        "overall_contact_backup": {
            "email": "myoshino@dom.wustl.edu", 
            "last_name": "Mihoko Yoshino, MD, PhD", 
            "phone": "314-362-8228"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Samuel Klein, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This aim will be evaluated by assessment of: i) fasting plasma glucose; ii) glycated hemoglobin (HbA1c); iii) use of diabetes medications and iv) resolution of Type 2 diabetes, defined as a fasting plasma glucose <126 mg/dL, 2-hr oral glucose tolerance test plasma glucose <200 mg/dL, HbA1c <6.5% and discontinuation of all diabetes medications.", 
            "measure": "Glycemic Control", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977560"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Liver and skeletal muscle insulin sensitivity, \u03b2-cell function, and cellular factors in skeletal muscle and adipose tissue that regulate glucose metabolism", 
                "measure": "Glucose metabolism", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "description": "This aim will be evaluated by assessing by administration of cognitive testing and brain MRI.", 
                "measure": "Neuronal Function", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "description": "This aim will be evaluated by using semi-structured interviews to assess accessibility and feasibility In addition, participants' time spent on intervention activities and delivery will be determined.", 
                "measure": "Acceptability and Feasibility of Intervention", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Dairy Council", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "American Egg Board", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}